Clinical Results and Safety Phase 2 clinical trials have reported encouraging weight loss outcomes, with participants receiving the highest doses achieving an average body weight reduction of approximately 24% over 48 weeks
The researchers wondered whether the genetic glitch also affects GLP-1, a gut hormone that plays an important role in blood sugar control after a meal by stimulating insulin release, slowing stomach emptying and reducing appetite
doi: 10.1016/j.bcp.2024.116192 77 YamazakiTTakahashiCTaniguchiYNarukawaMMisakaTAnoY
It is classified as a triple incretin receptor agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously
The problem is that research into proper dosing for sublingual use is not available
Triple receptor engagement raises complex questions about signaling balance, receptor selectivity, tissue-specific effects, cellular communication, and downstream gene expression pathways
